InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.600 -0.4 (-40%)+
Announcement
Release
27 Aug 2025 4:49PM
Price at Release
$1.000
Full Release
download
Summary
Cyclopharm Limited’s Half Yearly Report and Accounts detail the financial performance and operational highlights for the half year ended 30 June 2023. The company reported strong sales growth, particularly in their core product Technegas, due to increasing global demand and expansion into new markets. Cyclopharm also outlined progress in obtaining regulatory approvals in the United States and highlighted strategic investments in research and development to support future growth. The Group’s financial performance was characterized by higher revenues, controlled expenses, and continued investment in expanding its commercial capabilities. The Directors remain optimistic about the company’s long-term prospects, emphasizing the potential of new product launches and further geographic expansion.
Key Points
  • Cyclopharm Limited released its Half Yearly Report for the period ending 30 June 2023.
  • The Group achieved strong revenue growth, led by increased demand for Technegas.
  • Expansion into new international markets and progress in US regulatory approval for Technegas.
  • Continued investment in research, development, and commercial infrastructure.
  • The financial results showed higher sales revenues and controlled costs.
  • Management remains positive about the company’s long-term growth, citing new products and market expansion.
  • Directors declared an interim dividend for shareholders.
  • The report includes unaudited financial statements and analysis of operational performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.